Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Core Viewpoint - Aquestive Therapeutics, Inc. is set to report its second quarter results for the period ending June 30, 2025, and will provide updates on recent business developments on August 11, 2025 [1]. Company Overview - Aquestive is a pharmaceutical company focused on advancing medicines that significantly improve patients' lives through innovative science and delivery technologies [3]. - The company is developing orally administered products to deliver complex molecules, offering alternatives to invasive and inconvenient standard therapies [3]. - Currently, Aquestive has four commercialized products marketed by its licensees in the U.S. and globally, and it is the exclusive manufacturer of these licensed products [3]. - The company collaborates with other pharmaceutical companies to bring new molecules to market using proprietary technologies, such as PharmFilm® [3]. - Aquestive is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis, and an earlier-stage epinephrine prodrug topical gel for various dermatological conditions, including alopecia areata [3]. Upcoming Events - Management will host a conference call for investors on August 12, 2025, at 8:00 a.m. ET, with registration required for participation [2]. - A live webcast of the call will be available on the Investors section of the company's website, and a replay will be archived for 30 days [2].